Biomarker related to ischemic cardiomyopathy occurrence and development

A specific technology for ischemic cardiomyopathy, applied in the field of biomarkers, to achieve the effect of reducing mortality, timely gene diagnosis, and realizing early diagnosis

Inactive Publication Date: 2019-04-05
THE THIRD HOSPITAL OF HEBEI MEDICAL UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cardiovascular disease has gradually become a global and serious public health problem that affects human physical and mental health. However,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker related to ischemic cardiomyopathy occurrence and development

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Example 1 Screening for Gene Markers Related to Ischemic Cardiomyopathy

[0065] 1. Sample collection

[0066] 1) Collection of blood samples

[0067] Blood samples from 25 normal people and patients with ischemic cardiomyopathy were collected, and the EDTA anticoagulant tubes were allowed to stand for 10 minutes, then the serum was separated by centrifugation, and stored at -20°C for later use.

[0068] 2) Collection of tissue samples

[0069] Left ventricular tissue samples were collected from 25 patients with ischemic cardiomyopathy and from 10 non-cardiomyopathy deaths.

[0070] Inclusion criteria for patients with ischemic cardiomyopathy: refer to Burch's (1972) diagnostic criteria for ICM and the New York Heart Association (NYHA) cardiac function classification criteria to determine: (1) have a clear history of coronary heart disease (angina pectoris) , myocardial infarction more than half a year, electrocardiogram and enzyme abnormalities) evidence; (2) obviou...

Embodiment 2

[0083] Example 2 QPCR sequencing to verify the differential expression of PCYOX1L gene

[0084] 1. According to the detection results of high-throughput sequencing, the PCYOX1L gene was selected for large-sample QPCR verification.

[0085] 2. RNA extraction

[0086] Use QIAGEN's tissue RNA extraction kit to extract total RNA, and blood RNA extraction kit to extract blood RNA. For specific steps, refer to the instruction manual.

[0087] 3. Reverse transcription:

[0088] 1) Add dNTP mixture 1μl, Oligo dT primer 1μl, total RNA 2μg, add RNase FreeddH 2 O Make the total volume to 10 μl, carry out denaturation and annealing reaction on the PCR instrument, 65°C, 5min, place at 4°C after the reaction is completed.

[0089] 2) Construct a 20 μl reaction system, continue to add 4 μl of 5×Primer Script Buffer, 0.5 μl of RNase Inhibitor, 0.5 μl of Prime Script RTase, RNase Free ddH 2 O 5.0 μl, carry out the reverse transcription reaction on the PCR instrument according to the follow...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a biomarker related to ischemic cardiomyopathy occurrence and development. A gene is PCYOX1L; high-throughput sequencing finds out that the expression of the PCYOX1L gene in the body of a patient with ischemic cardiomyopathy is up-regulated; further verification proves that the PCYOX1L gene exactly has differential expression in the body of the patient with the ischemic cardiomyopathy and the results shows that the PCYOX1L can be used as the biomarker applied to clinical diagnosis of the ischemic cardiomyopathy.

Description

technical field [0001] The invention relates to the field of biomedicine, and relates to a biomarker related to the occurrence and development of ischemic cardiomyopathy, and the biomarker is PCYOX1L. Background technique [0002] Ischemic cardiomyopathy (ICM) refers to a clinical syndrome characterized by heart failure and heart enlargement caused by myocardial ischemia. fibrosis, multifocal myocardial infarction, etc. In terms of clinical symptoms, ischemic cardiomyopathy is very similar to primary dilated cardiomyopathy (Dilated Cardiomyopathy, DCM), but unlike DCM, ischemic cardiomyopathy usually has a clearer etiology. Except for a very small number of myocardial ischemia caused by vasospasm, vasculitis or vascular embolism, the vast majority of ischemic cardiomyopathy is caused by coronary atherosclerosis. Therefore, ischemic cardiomyopathy is generally considered to be a cardiac syndrome at the end stage of coronary atherosclerotic heart disease (CHD). [0003] Isc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6883G01N33/68
CPCC12Q1/6883G01N33/68G01N2800/325
Inventor 李海滨曹海育
Owner THE THIRD HOSPITAL OF HEBEI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap